While the firm’s mind and money continues to gear towards branded and novel drugs, India’s Sun Pharma still maintains a mammoth global generics business, including in the US where Sun saw a healthy leap in sales during its financial second quarter.
Sun Pharma is pleased with ongoing efforts by the US Food and Drug Administration to facilitate and speed up development for complex generics, but feels more can still be done to guide generics manufacturers.
“We’ve indicated that there are products for which there is lack of clarity from a regulatory point of view,” commented...
Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.
A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.
Novartis has filed an immediate appeal after a US district court ruled that MSN Labs would not infringe one of its key patents shielding its $7.8bn Entresto brand, and denied the originator injunctive relief.
Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.
Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.
